The Growing America's Pharmaceutical Supply Act modifies federal rules to help address drug shortages by giving pharmaceutical outsourcing facilities a grace period to continue producing and distributing medications after a shortage is declared. Specifically, the bill extends a "tail period" of up to 180 calendar days that allows these facilities to keep supplying drugs to the market, rather than having to stop immediately once a shortage ends. This change affects outsourcing facilities—specialized compounding operations that produce medications when commercial supplies run short—by giving them more flexibility to help mitigate supply disruptions without immediately halting production. The bill contains no new funding requirements, as it simply adjusts existing regulations under the Federal Food, Drug, and Cosmetic Act. The legislation was introduced in February 2026 and referred to the House Committee on Energy and Commerce.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.